{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:45:30Z","timestamp":1781149530215,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":58,"publisher":"Springer US","isbn-type":[{"value":"9781493998449","type":"print"},{"value":"9781493998456","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-4939-9845-6_1","type":"book-chapter","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T22:04:07Z","timestamp":1569967447000},"page":"3-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Snake- and Spider-Venom-Derived Toxins as Lead Compounds for Drug Development"],"prefix":"10.1007","author":[{"given":"Philip","family":"Lazarovici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,2]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1517\/14712598.2011.621940","volume":"11","author":"GF King","year":"2011","unstructured":"King GF (2011) Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin Biol Ther 11:1469\u20131484. https:\/\/doi.org\/10.1517\/14712598.2011.621940","journal-title":"Expert Opin Biol Ther"},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fphar.2018.00145","volume":"9","author":"JM Souza de","year":"2018","unstructured":"de Souza JM, Goncalves BDC, Gomez MV, Vieira LB, Ribeiro FM (2018) Animal toxins as therapeutic tools to treat neurodegenerative diseases. Front Pharmacol 9:145. https:\/\/doi.org\/10.3389\/fphar.2018.00145","journal-title":"Front Pharmacol"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2174\/1568026615666150217110710","volume":"15","author":"SL Morales-Lazaro","year":"2015","unstructured":"Morales-Lazaro SL, Hernandez-Garcia E, Serrano-Flores B, Rosenbaum T (2015) Organic toxins as tools to understand ion channel mechanisms and structure. Curr Top Med Chem 15:581\u2013603. https:\/\/doi.org\/10.2174\/1568026615666150217110710","journal-title":"Curr Top Med Chem"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"589 LP","DOI":"10.1161\/01.HYP.17.4.589","volume":"17","author":"DW Cushman","year":"1991","unstructured":"Cushman DW, Ondetti MA (1991) History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 17:589 LP\u2013589592. http:\/\/hyper.ahajournals.org\/content\/17\/4\/589.abstract","journal-title":"Hypertension"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.toxicon.2011.03.017","volume":"59","author":"CY Koh","year":"2012","unstructured":"Koh CY, Kini RM (2012) From snake venom toxins to therapeutics \u2013 cardiovascular examples. Toxicon 59:497\u2013506. https:\/\/doi.org\/10.1016\/j.toxicon.2011.03.017","journal-title":"Toxicon"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1586\/14789450.5.5.731","volume":"5","author":"S Liang","year":"2008","unstructured":"Liang S (2008) Proteome and peptidome profiling of spider venoms. Expert Rev Proteomics 5:731\u2013746. https:\/\/doi.org\/10.1586\/14789450.5.5.731","journal-title":"Expert Rev Proteomics"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1038\/ncomms4765","volume":"5","author":"KW Sanggaard","year":"2014","unstructured":"Sanggaard KW, Bechsgaard JS, Fang X, Duan J, Dyrlund TF, Gupta V, Jiang X, Cheng L, Fan D, Feng Y, Han L, Huang Z, Wu Z, Liao L, Settepani V, Thogersen IB, Vanthournout B, Wang T, Zhu Y, Funch P, Enghild JJ, Schauser L, Andersen SU, Villesen P, Schierup MH, Bilde T, Wang J (2014) Spider genomes provide insight into composition and evolution of venom and silk. Nat Commun 5:3765. https:\/\/doi.org\/10.1038\/ncomms4765","journal-title":"Nat Commun"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3\u201326","journal-title":"Adv Drug Deliv Rev"},{"key":"1_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ht7010004","volume":"7","author":"A Roy","year":"2018","unstructured":"Roy A (2018) Early probe and drug discovery in academia: a minireview. High Throughput 7:E4. https:\/\/doi.org\/10.3390\/ht7010004","journal-title":"High Throughput"},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrd1133","volume":"2","author":"BL Bray","year":"2003","unstructured":"Bray BL (2003) Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov 2:587\u2013593. https:\/\/doi.org\/10.1038\/nrd1133","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2174\/1567201812666151012113221","volume":"13","author":"P Kaur","year":"2016","unstructured":"Kaur P, Garg V, Gulati M, Singh SK (2016) Oral delivery of antidiabetic polypeptide-k: journey so far and the road ahead. Curr Drug Deliv 13:236\u2013244","journal-title":"Curr Drug Deliv"},{"key":"1_CR12","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.4155\/tde.13.104","volume":"4","author":"BJ Bruno","year":"2013","unstructured":"Bruno BJ, Miller GD, Lim CS (2013) Basics and recent advances in peptide and protein drug delivery. Ther Deliv 4:1443\u20131467. https:\/\/doi.org\/10.4155\/tde.13.104","journal-title":"Ther Deliv"},{"key":"1_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10030126","volume":"10","author":"S Peigneur","year":"2018","unstructured":"Peigneur S, Tytgat J (2018) Toxins in drug discovery and pharmacology. Toxins (Basel) 10:E126. https:\/\/doi.org\/10.3390\/toxins10030126","journal-title":"Toxins (Basel)"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.toxicon.2014.10.020","volume":"92","author":"AL Harvey","year":"2014","unstructured":"Harvey AL (2014) Toxins and drug discovery. Toxicon 92:193\u2013200. https:\/\/doi.org\/10.1016\/j.toxicon.2014.10.020","journal-title":"Toxicon"},{"key":"1_CR15","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3892\/br.2017.909","volume":"6","author":"S Mathur","year":"2017","unstructured":"Mathur S, Hoskins C (2017) Drug development: lessons from nature. Biomed Rep 6:612\u2013614. https:\/\/doi.org\/10.3892\/br.2017.909","journal-title":"Biomed Rep"},{"key":"1_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.tree.2012.10.020","volume":"28","author":"NR Casewell","year":"2013","unstructured":"Casewell NR, Wuster W, Vonk FJ, Harrison RA, Fry BG (2013) Complex cocktails: the evolutionary novelty of venoms. Trends Ecol Evol 28:219\u2013229. https:\/\/doi.org\/10.1016\/j.tree.2012.10.020","journal-title":"Trends Ecol Evol"},{"key":"1_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.toxlet.2018.02.004","volume":"287","author":"S Xiong","year":"2018","unstructured":"Xiong S, Huang C (2018) Synergistic strategies of predominant toxins in snake venoms. Toxicol Lett 287:142\u2013154. https:\/\/doi.org\/10.1016\/j.toxlet.2018.02.004","journal-title":"Toxicol Lett"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2165\/11595010-000000000-00000","volume":"71","author":"HB Starnes","year":"2011","unstructured":"Starnes HB, Patel AA, Stouffer GA (2011) Optimal use of platelet glycoprotein IIb\/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions. Drugs 71:2009\u20132030. https:\/\/doi.org\/10.2165\/11595010-000000000-00000","journal-title":"Drugs"},{"key":"1_CR19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0021-9258(18)54042-4","volume":"268","author":"RM Scarborough","year":"1993","unstructured":"Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF (1993) Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 268:1066\u20131073","journal-title":"J Biol Chem"},{"key":"1_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2165\/00003088-200342080-00001","volume":"42","author":"IC Gilchrist","year":"2003","unstructured":"Gilchrist IC (2003) Platelet glycoprotein IIb\/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide. Clin Pharmacokinet 42:703\u2013720. https:\/\/doi.org\/10.2165\/00003088-200342080-00001","journal-title":"Clin Pharmacokinet"},{"key":"1_CR21","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/cpt.974","volume":"104","author":"R Kawakami","year":"2017","unstructured":"Kawakami R, Lee CYW, Scott C, Bailey KR, Schirger JA, Chen HH, Benike SL, Cannone V, Martin FL, Sangaralingham SJ, Ichiki T, Burnett JCJ (2017) A human study to evaluate safety, tolerability, and cyclic GMP activating properties of Cenderitide in subjects with stable chronic heart failure. Clin Pharmacol Ther 104:546. https:\/\/doi.org\/10.1002\/cpt.974","journal-title":"Clin Pharmacol Ther"},{"key":"1_CR22","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/toxins3111420","volume":"3","author":"T Momic","year":"2011","unstructured":"Momic T, Arlinghaus FT, Arien-Zakay H, Katzhendler J, Eble JA, Marcinkiewicz C, Lazarovici P (2011) Pharmacological aspects of Vipera xantina palestinae venom. Toxins (Basel) 3:1420\u20131432. https:\/\/doi.org\/10.3390\/toxins3111420","journal-title":"Toxins (Basel)"},{"key":"1_CR23","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3390\/toxins4100862","volume":"4","author":"T Momic","year":"2012","unstructured":"Momic T, Cohen G, Reich R, Arlinghaus FT, Eble JA, Marcinkiewicz C, Lazarovici P (2012) Vixapatin (VP12), a c-type lectin-protein from Vipera xantina palestinae venom: characterization as a novel anti-angiogenic compound. Toxins (Basel) 4:862\u2013877. https:\/\/doi.org\/10.3390\/toxins4100862","journal-title":"Toxins (Basel)"},{"key":"1_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/DDDT.S72844","volume":"9","author":"T Momic","year":"2015","unstructured":"Momic T, Katzhendler J, Shai E, Noy E, Senderowitz H, Eble JA, Marcinkiewicz C, Varon D, Lazarovici P (2015) Vipegitide: a folded peptidomimetic partial antagonist of alpha2beta1 integrin with antiplatelet aggregation activity. Drug Des Devel Ther 9:291\u2013304. https:\/\/doi.org\/10.2147\/DDDT.S72844","journal-title":"Drug Des Devel Ther"},{"key":"1_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.toxicon.2013.01.001","volume":"64","author":"FT Arlinghaus","year":"2013","unstructured":"Arlinghaus FT, Momic T, Ammar NA, Shai E, Spectre G, Varon D, Marcinkiewicz C, Heide H, Lazarovici P, Eble JA (2013) Identification of alpha2beta1 integrin inhibitor VP-i with anti-platelet properties in the venom of Vipera palaestinae. Toxicon 64:96\u2013105. https:\/\/doi.org\/10.1016\/j.toxicon.2013.01.001","journal-title":"Toxicon"},{"key":"1_CR26","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.4161\/cbt.8.15.8999","volume":"8","author":"I Staniszewska","year":"2009","unstructured":"Staniszewska I, Walsh EM, Rothman VL, Gaathon A, Tuszynski GP, Calvete JJ, Lazarovici P, Marcinkiewicz C (2009) Effect of VP12 and viperistatin on inhibition of collagen-receptor-dependent melanoma metastasis. Cancer Biol Ther 8:1507\u20131516","journal-title":"Cancer Biol Ther"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/toxins9030107","volume":"9","author":"A Lahiani","year":"2017","unstructured":"Lahiani A, Yavin E, Lazarovici P (2017) The molecular basis of toxins\u2019 interactions with intracellular signaling via discrete portals. Toxins (Basel) 9:1\u201358. https:\/\/doi.org\/10.3390\/toxins9030107","journal-title":"Toxins (Basel)"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.toxicon.2008.05.020","volume":"52","author":"GF King","year":"2008","unstructured":"King GF, Gentz MC, Escoubas P, Nicholson GM (2008) A rational nomenclature for naming peptide toxins from spiders and other venomous animals. Toxicon 52:264\u2013276. https:\/\/doi.org\/10.1016\/j.toxicon.2008.05.020","journal-title":"Toxicon"},{"key":"1_CR29","doi-asserted-by":"publisher","first-page":"13974","DOI":"10.1074\/jbc.M116.725978","volume":"291","author":"A Shcherbatko","year":"2016","unstructured":"Shcherbatko A, Rossi A, Foletti D, Zhu G, Bogin O, Galindo Casas M, Rickert M, Hasa-Moreno A, Bartsevich V, Crameri A, Steiner AR, Henningsen R, Gill A, Pons J, Shelton DL, Rajpal A, Strop P (2016) Engineering highly potent and selective microproteins against Nav1.7 Sodium Channel for treatment of pain. J Biol Chem 291:13974\u201313986. https:\/\/doi.org\/10.1074\/jbc.M116.725978","journal-title":"J Biol Chem"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1021\/jm501765v","volume":"58","author":"JK Murray","year":"2015","unstructured":"Murray JK, Ligutti J, Liu D, Zou A, Poppe L, Li H, Andrews KL, Moyer BD, McDonough SI, Favreau P, Stocklin R, Miranda LP (2015) Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel. J Med Chem 58:2299\u20132314. https:\/\/doi.org\/10.1021\/jm501765v","journal-title":"J Med Chem"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1016\/j.bmc.2017.09.029","volume":"26","author":"MW Pennington","year":"2017","unstructured":"Pennington MW, Czerwinski A, Norton RS (2017) Peptide therapeutics from venom: current status and potential. Bioorg Med Chem 26:2738. https:\/\/doi.org\/10.1016\/j.bmc.2017.09.029","journal-title":"Bioorg Med Chem"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.toxicon.2006.09.014","volume":"49","author":"BT Priest","year":"2007","unstructured":"Priest BT, Blumenthal KM, Smith JJ, Warren VA, Smith MM (2007) ProTx-I and ProTx-II: gating modifiers of voltage-gated sodium channels. Toxicon 49:194\u2013201. https:\/\/doi.org\/10.1016\/j.toxicon.2006.09.014","journal-title":"Toxicon"},{"key":"1_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep39662","volume":"7","author":"M Flinspach","year":"2017","unstructured":"Flinspach M, Xu Q, Piekarz AD, Fellows R, Hagan R, Gibbs A, Liu Y, Neff RA, Freedman J, Eckert WA, Zhou M, Bonesteel R, Pennington MW, Eddinger KA, Yaksh TL, Hunter M, Swanson RV, Wickenden AD (2017) Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor. Sci Rep 7:39662. https:\/\/doi.org\/10.1038\/srep39662","journal-title":"Sci Rep"},{"key":"1_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.peptides.2013.03.011","volume":"44","author":"JD Revell","year":"2013","unstructured":"Revell JD, Lund P-E, Linley JE, Metcalfe J, Burmeister N, Sridharan S, Jones C, Jermutus L, Bednarek MA (2013) Potency optimization of Huwentoxin-IV on hNav1.7: a neurotoxin TTX-S sodium-channel antagonist from the venom of the Chinese bird-eating spider Selenocosmia huwena. Peptides 44:40\u201346. https:\/\/doi.org\/10.1016\/j.peptides.2013.03.011","journal-title":"Peptides"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.2174\/1570159X11311060005","volume":"11","author":"S Lee","year":"2013","unstructured":"Lee S (2013) Pharmacological inhibition of voltage-gated ca(2+) channels for chronic pain relief. Curr Neuropharmacol 11:606\u2013620. https:\/\/doi.org\/10.2174\/1570159X11311060005","journal-title":"Curr Neuropharmacol"},{"key":"1_CR36","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1124\/jpet.105.087023","volume":"314","author":"LB Vieira","year":"2005","unstructured":"Vieira LB, Kushmerick C, Hildebrand ME, Garcia E, Stea A, Cordeiro MN, Richardson M, Gomez MV, Snutch TP (2005) Inhibition of high voltage-activated calcium channels by spider toxin PnTx3-6. J Pharmacol Exp Ther 314:1370\u20131377. https:\/\/doi.org\/10.1124\/jpet.105.087023","journal-title":"J Pharmacol Exp Ther"},{"key":"1_CR37","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.pain.2011.04.015","volume":"152","author":"GD Dalmolin","year":"2011","unstructured":"Dalmolin GD, Silva CR, Rigo FK, Gomes GM, Cordeiro M d N, Richardson M, Silva MAR, Prado MAM, Gomez MV, Ferreira J (2011) Antinociceptive effect of Brazilian armed spider venom toxin Tx3-3 in animal models of neuropathic pain. Pain 152:2224\u20132232. https:\/\/doi.org\/10.1016\/j.pain.2011.04.015","journal-title":"Pain"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1021\/mp500809f","volume":"12","author":"J Wang","year":"2015","unstructured":"Wang J, Yadav V, Smart AL, Tajiri S, Basit AW (2015) Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol Pharm 12:966\u2013973. https:\/\/doi.org\/10.1021\/mp500809f","journal-title":"Mol Pharm"},{"key":"1_CR39","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1021\/jm960154i","volume":"39","author":"G Byk","year":"1996","unstructured":"Byk G, Halle D, Zeltser I, Bitan G, Selinger Z, Gilon C (1996) Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. J Med Chem 39:3174\u20133178. https:\/\/doi.org\/10.1021\/jm960154i","journal-title":"J Med Chem"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1210\/endo.142.1.7880","volume":"142","author":"M Afargan","year":"2001","unstructured":"Afargan M, Janson ET, Gelerman G, Rosenfeld R, Ziv O, Karpov O, Wolf A, Bracha M, Shohat D, Liapakis G, Gilon C, Hoffman A, Stephensky D, Oberg K (2001) Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 142:477\u2013486. https:\/\/doi.org\/10.1210\/endo.142.1.7880","journal-title":"Endocrinology"},{"key":"1_CR41","doi-asserted-by":"publisher","first-page":"15148","DOI":"10.1002\/chem.201501600","volume":"21","author":"UK Marelli","year":"2015","unstructured":"Marelli UK, Ovadia O, Frank AO, Chatterjee J, Gilon C, Hoffman A, Kessler H (2015) Cis-peptide bonds: a key for intestinal permeability of peptides? Chemistry 21:15148\u201315152. https:\/\/doi.org\/10.1002\/chem.201501600","journal-title":"Chemistry"},{"key":"1_CR42","doi-asserted-by":"publisher","first-page":"16405","DOI":"10.1002\/anie.201709709","volume":"56","author":"M Weinmuller","year":"2017","unstructured":"Weinmuller M, Rechenmacher F, Kiran Marelli U, Reichart F, Kapp TG, Rader AFB, Di Leva FS, Marinelli L, Novellino E, Munoz-Felix JM, Hodivala-Dilke K, Schumacher A, Fanous J, Gilon C, Hoffman A, Kessler H (2017) Overcoming the lack of oral availability of cyclic hexapeptides: design of a selective and orally available ligand for the integrin alphavbeta3. Angew Chem Int Ed Engl 56:16405\u201316409. https:\/\/doi.org\/10.1002\/anie.201709709","journal-title":"Angew Chem Int Ed Engl"},{"key":"1_CR43","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.2174\/0929867324666170605091546","volume":"24","author":"H Waheed","year":"2017","unstructured":"Waheed H, Moin SF, Choudhary MI (2017) Snake venom: from deadly toxins to life-saving therapeutics. Curr Med Chem 24:1874\u20131891. https:\/\/doi.org\/10.2174\/0929867324666170605091546","journal-title":"Curr Med Chem"},{"key":"1_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/clpt.1994.152","volume":"56","author":"JS Barrett","year":"1994","unstructured":"Barrett JS, Murphy G, Peerlinck K, De Lepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout J (1994) Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb\/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 56:377\u2013388","journal-title":"Clin Pharmacol Ther"},{"key":"1_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/ehjcvp\/pvv043","volume":"2","author":"J Wojta","year":"2016","unstructured":"Wojta J (2016) Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states. Eur Hear J Cardiovasc Pharmacother 2:106\u2013107. https:\/\/doi.org\/10.1093\/ehjcvp\/pvv043","journal-title":"Eur Hear J Cardiovasc Pharmacother"},{"key":"1_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2141.2009.07605.x","volume":"145","author":"SM Flight","year":"2009","unstructured":"Flight SM, Johnson LA, Du QS, Warner RL, Trabi M, Gaffney PJ, Lavin MF, de Jersey J, Masci PP (2009) Textilinin-1, an alternative anti-bleeding agent to aprotinin: importance of plasmin inhibition in controlling blood loss. Br J Haematol 145:207\u2013211. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07605.x","journal-title":"Br J Haematol"},{"key":"1_CR47","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.toxicon.2010.12.010","volume":"59","author":"STH Earl","year":"2012","unstructured":"Earl STH, Masci PP, de Jersey J, Lavin MF, Dixon J (2012) Drug development from Australian elapid snake venoms and the venomics pipeline of candidates for haemostasis: Textilinin-1 (Q8008), Haempatch (Q8009) and CoVase (V0801). Toxicon 59:456\u2013463. https:\/\/doi.org\/10.1016\/j.toxicon.2010.12.010","journal-title":"Toxicon"},{"key":"1_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8030078","volume":"8","author":"JR Deuis","year":"2016","unstructured":"Deuis JR, Wingerd JS, Winter Z, Durek T, Dekan Z, Sousa SR, Zimmermann K, Hoffmann T, Weidner C, Nassar MA, Alewood PF, Lewis RJ, Vetter I (2016) Analgesic effects of GpTx-1, PF-04856264 and CNV1014802 in a mouse model of NaV1.7-mediated pain. Toxins (Basel) 8:E78. https:\/\/doi.org\/10.3390\/toxins8030078","journal-title":"Toxins (Basel)"},{"key":"1_CR49","doi-asserted-by":"publisher","first-page":"13063","DOI":"10.1021\/jacs.7b06506","volume":"139","author":"ZVF Wright","year":"2017","unstructured":"Wright ZVF, McCarthy S, Dickman R, Reyes FE, Sanchez-Martinez S, Cryar A, Kilford I, Hall A, Takle AK, Topf M, Gonen T, Thalassinos K, Tabor AB (2017) The role of disulfide bond replacements in analogues of the tarantula toxin ProTx-II and their effects on inhibition of the voltage-gated sodium Ion Channel Nav1.7. J Am Chem Soc 139:13063\u201313075. https:\/\/doi.org\/10.1021\/jacs.7b06506","journal-title":"J Am Chem Soc"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"6623","DOI":"10.1021\/jm500687u","volume":"57","author":"JH Park","year":"2014","unstructured":"Park JH, Carlin KP, Wu G, Ilyin VI, Musza LL, Blake PR, Kyle DJ (2014) Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels. J Med Chem 57:6623\u20136631. https:\/\/doi.org\/10.1021\/jm500687u","journal-title":"J Med Chem"},{"key":"1_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/09298665113206660119","volume":"21","author":"Y Liu","year":"2014","unstructured":"Liu Y, Wu Z, Tang D, Xun X, Liu L, Li X, Nie D, Xiang Y, Yi J, Yi J (2014) Analgesic effects of Huwentoxin-IV on animal models of inflammatory and neuropathic pain. Protein Pept Lett 21:153\u2013158","journal-title":"Protein Pept Lett"},{"key":"1_CR52","first-page":"232","volume":"287","author":"KA Sluka","year":"1998","unstructured":"Sluka KA (1998) Blockade of N- and P\/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. J Pharmacol Exp Ther 287:232\u2013237","journal-title":"J Pharmacol Exp Ther"},{"key":"1_CR53","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1152\/jn.1999.81.6.2620","volume":"81","author":"J Nebe","year":"1999","unstructured":"Nebe J, Ebersberger A, Vanegas H, Schaible HG (1999) Effects of omega-agatoxin IVA, a P-type calcium channel antagonist, on the development of spinal neuronal hyperexcitability caused by knee inflammation in rats. J Neurophysiol 81:2620\u20132626. https:\/\/doi.org\/10.1152\/jn.1999.81.6.2620","journal-title":"J Neurophysiol"},{"key":"1_CR54","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.toxicon.2004.02.004","volume":"43","author":"ME Adams","year":"2004","unstructured":"Adams ME (2004) Agatoxins: ion channel specific toxins from the American funnel web spider, Agelenopsis aperta. Toxicon 43:509\u2013525. https:\/\/doi.org\/10.1016\/j.toxicon.2004.02.004","journal-title":"Toxicon"},{"key":"1_CR55","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1074\/jbc.M513542200","volume":"281","author":"Z Liu","year":"2006","unstructured":"Liu Z, Dai J, Dai L, Deng M, Hu Z, Hu W, Liang S (2006) Function and solution structure of Huwentoxin-X, a specific blocker of N-type calcium channels, from the Chinese bird spider Ornithoctonus huwena. J Biol Chem 281:8628\u20138635. https:\/\/doi.org\/10.1074\/jbc.M513542200","journal-title":"J Biol Chem"},{"key":"1_CR56","doi-asserted-by":"publisher","first-page":"8341","DOI":"10.1021\/bi00026a015","volume":"34","author":"R Newcomb","year":"1995","unstructured":"Newcomb R, Palma A, Fox J, Gaur S, Lau K, Chung D, Cong R, Bell JR, Horne B, Nadasdi L (1995) SNX-325, a novel calcium antagonist from the spider Segestria florentina. Biochemistry 34:8341\u20138347","journal-title":"Biochemistry"},{"key":"1_CR57","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.neuropharm.2007.03.012","volume":"52","author":"H Kubista","year":"2007","unstructured":"Kubista H, Mafra RA, Chong Y, Nicholson GM, Beirao PSL, Cruz JS, Boehm S, Nentwig W, Kuhn-Nentwig L (2007) CSTX-1, a toxin from the venom of the hunting spider Cupiennius salei, is a selective blocker of L-type calcium channels in mammalian neurons. Neuropharmacology 52:1650\u20131662. https:\/\/doi.org\/10.1016\/j.neuropharm.2007.03.012","journal-title":"Neuropharmacology"},{"key":"1_CR58","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.bcp.2014.02.008","volume":"89","author":"JK Klint","year":"2014","unstructured":"Klint JK, Berecki G, Durek T, Mobli M, Knapp O, King GF, Adams DJ, Alewood PF, Rash LD (2014) Isolation, synthesis and characterization of omega-TRTX-Cc1a, a novel tarantula venom peptide that selectively targets L-type Cav channels. Biochem Pharmacol 89:276\u2013286. https:\/\/doi.org\/10.1016\/j.bcp.2014.02.008","journal-title":"Biochem Pharmacol"}],"container-title":["Methods in Molecular Biology","Snake and Spider Toxins"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-9845-6_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T23:45:32Z","timestamp":1611445532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-9845-6_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,2]]},"ISBN":["9781493998449","9781493998456"],"references-count":58,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-9845-6_1","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,2]]},"assertion":[{"value":"2 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}